(Bloomberg) -- Banks are lining up approximately $2.35 billion in debt to support the proposed leveraged buyout of Patterson Companies Inc., a supplier of everything from dental equipment to drugs for pets and livestock. Most Read from Bloomberg They Built a Secret Apartment in a Mall. Now the Mall Is Dying. Why Did the Government Declare War on My Adorable Tiny Truck? Chicago Transit Faces ‘Doomsday Scenario,’ Regional Agency Says LA Faces $1 Billion Budget Hole, Warns of Thousands of Layoffs Libraries Warn They Could Be ‘Cut off at the Knees’ by DOGE The financing is expected to be comprised of a $1.85 billion term loan led by UBS Group AG as well as approximately $500 million in high-yield bonds led by Citigroup Inc., according to people familiar with the transaction. Patient Square Capital, a private equity firm launched in 2020, is expected to use the funds for its $4.1 billion acquisition of the nearly 150-year-old animal health-care conglomerate. A transaction could launch into the syndicated leveraged-loan and high-yield bond markets before the end of April, said the people, who requested anonymity to discuss a private matter. The break down of debt between bonds and loans could change, they added. UBS, Citi and Wells Fargo & Co. are arranging the financing package, according to the people familiar. Spokespeople for the three banks declined to comment while representatives for Patterson and Patient Square didn’t respond to requests for comment. The acquisition financing would help rouse what’s been a sleepy first quarter for leveraged capital markets, where deals have largely been skewed toward less lucrative refinancing or repricing of existing debt. However, there are other signs of an uptick in acquisition-fueled debt. Lenders launched a €7.45 billion ($8 billion) deal to support Clayton Dubilier & Rice’s purchase of a stake in Sanofi SA’s consumer health division, Bloomberg News reported on Monday. And last week, energy drink maker Celsius Holdings Inc. raised $900 million to fund its acquisition of rival Alani Nutrition LLC. Patterson agreed to be acquired by Patient Square in December, the company said in a press release at the time. The $4.1 billion value included committed debt financing from the banks and the refinancing of Patterson’s loans backed by outstanding invoices, according to the release. The acquisition, which would make Patterson a private company, will be subject to a shareholder vote in April, the company said in a filing with the US Securities and Exchange Commission on Monday. Headquartered in St. Paul, Minnesota, Patterson provides products, technology and services to dental and animal-health customers. Story Continues (Updates with details of banks leading the two debt components in second paragraph.) Most Read from Bloomberg Businessweek The Richest Americans Kept the Economy Booming. What Happens When They Stop Spending? A New ‘China Shock’ Is Destroying Jobs Around the World Google Is Searching for an Answer to ChatGPT How TD Became America’s Most Convenient Bank for Money Launderers Tesla’s Gamble on MAGA Customers Won’t Work ©2025 Bloomberg L.P. View Comments
Pet Supplier Patterson Eyes $2.35 Billion in Buyout Debt
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...